eligibility_summary
Inclusion: consent, R/R B‑cell malignancy with measurable disease, ECOG 0–2, eGFR ≥50 (SS1/3/4) or ≥30 plus BTKi‑naive/previous without progression (SS2). Contraception (no gamete donation), pregnancy test 10–14 d pre‑dose, protection post‑dose 30/60/90 d per drug. Exclusion: treatment‑naive, leptomeningeal or uncontrolled brain mets, other malignancy ≤2 y, auto‑SCT or CAR‑T ≤3 mo, allo‑SCT with GVHD/immunosupp (SS1/2) or any allo (SS3/4), severe drug allergy, prior BCL‑2 (unless relapse ≥24 mo, SS1), prior CD20×CD3 (SS3/4), prior zanubrutinib intolerance (SS2).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1b/2 master-protocol in relapsed/refractory B‑cell malignancies tests BGB‑16673, an oral BTK degrader (targeted protein degradation via proteasome) combined with: 1) Sonrotoclax (BGB‑11417), an oral selective BCL‑2 inhibitor (BH3 mimetic) inducing apoptosis, 2) Zanubrutinib, an oral covalent BTK inhibitor blocking B‑cell receptor (BCR) signaling, 3) Mosunetuzumab, a SC CD20×CD3 bispecific antibody redirecting T cells to kill CD20+ B cells, 4) Glofitamab, an IV CD20×CD3 bispecific, with obinutuzumab (anti‑CD20 type II mAb) pretreatment for B‑cell debulking/CRS risk mitigation. Targets/pathways: BTK degradation/inhibition (BCR signaling), BCL‑2 (apoptosis), CD20 on malignant B cells and CD3 on T cells (T‑cell cytotoxicity). Primary target cells: malignant CD20+ B cells, effector cells: T cells.